Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.

Qin Q, Zhang C, Yang X, Zhu H, Yang B, Cai J, Cheng H, Ma J, Lu J, Zhan L, Liu J, Liu Z, Xu L, Sun X.

PLoS One. 2013 Nov 15;8(11):e79864. doi: 10.1371/journal.pone.0079864. eCollection 2013.

2.
3.

Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.

Qiu M, Yang X, Hu J, Ding X, Jiang F, Yin R, Xu L.

PLoS One. 2013 Aug 19;8(8):e72251. doi: 10.1371/journal.pone.0072251. eCollection 2013. Review.

4.

Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.

Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, Zhang W, Qian J, Wang J, Chen H, Wei Q, Han B, Lu D.

PLoS One. 2012;7(3):e33200. doi: 10.1371/journal.pone.0033200. Epub 2012 Mar 29.

5.

No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.

Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, Heist RS, Rosell R, Booton R, Wei Q.

Lung Cancer. 2011 Jun;72(3):370-7. doi: 10.1016/j.lungcan.2010.10.011. Epub 2010 Nov 13.

6.

Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.

Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H, Zhong R, Xu Y, Wu J, Yu D, Wu T, Zhang X, Nie S, Miao X, Lin D.

Lung Cancer. 2011 Jul;73(1):110-5. doi: 10.1016/j.lungcan.2010.11.004. Epub 2010 Dec 3.

PMID:
21129812
7.

Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.

Cheng H, Qin Q, Sun X, Li F, Sun N, Cheng L, Lu Z, Chen B.

Technol Cancer Res Treat. 2013 Oct;12(5):473-82. doi: 10.7785/tcrt.2012.500337. Epub 2013 Apr 24.

PMID:
23617284
8.

Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.

Zhang L, Ma W, Li Y, Wu J, Shi GY.

Genet Mol Res. 2014 Jan 14;13(1):228-36. doi: 10.4238/2014.January.14.2.

9.

The XPD Lys751Gln polymorphism has predictive value in colorectal cancer patients receiving oxaliplatin-based chemotherapy: a systemic review and meta-analysis.

Qian YY, Liu XY, Pei D, Xu JL, Shen H, Chen XF, Liu YQ, Shen LZ, Shu YQ.

Asian Pac J Cancer Prev. 2014;15(22):9699-706. Review.

10.

Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.

Li XD, Han JC, Zhang YJ, Li HB, Wu XY.

Asian Pac J Cancer Prev. 2013;14(1):145-8.

11.

Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.

Kim SH, Lee GW, Lee MJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim IS, Lee S, Oh SY.

Lung Cancer. 2012 Sep;77(3):578-84. doi: 10.1016/j.lungcan.2012.04.016. Epub 2012 May 18.

PMID:
22608006
12.

[Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].

Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Sun Y, Xu BH, Lin DX.

Zhonghua Yi Xue Za Zhi. 2005 Apr 13;85(14):972-5. Chinese.

PMID:
16061005
15.

Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis.

Ma Q, Qi C, Tie C, Guo Z.

Gene. 2013 Nov 10;530(2):309-14. doi: 10.1016/j.gene.2013.08.053. Epub 2013 Aug 23. Review.

PMID:
23973729
16.

Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.

Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, Pan LX, Tang JH.

Asian Pac J Cancer Prev. 2009;10(5):859-64.

17.

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.

Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, Song Y.

Med Oncol. 2011 Mar;28(1):315-21. doi: 10.1007/s12032-010-9443-1. Epub 2010 Feb 9. Review.

PMID:
20143185
18.

Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.

Booton R, Ward T, Heighway J, Taylor P, Power F, Ashcroft L, Morris J, Thatcher N.

Cancer. 2006 Jun 1;106(11):2421-7.

19.

Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.

Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, Gregori D, DeMarchi M, Scagliotti GV.

Clin Cancer Res. 2007 May 15;13(10):2876-81.

20.

Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.

Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.

Am J Clin Oncol. 2010 Oct;33(5):489-94. doi: 10.1097/COC.0b013e3181b9cedc.

PMID:
20351547
Items per page

Supplemental Content

Write to the Help Desk